Cite

    Peter C Taylor et al.. “Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.” Annals of the rheumatic diseases, vol. 81, no. 3, 2022, pp. 335–343. http://access.bl.uk/ark:/81055/vdc_100151273751.0x000056